natgillin/translations-raw huggingface dataset:
The antibody, or an antigen-binding portion thereof, for use in a method as defined in Claim 19, wherein the tumor cells are derived from liver tissue. 
Antitijelo, ili njegov antigen-vezujući dio, naznačeni time, što upotrebljavaju metodu definiranu u Zahtevu 19, pri čemu su tumorske stanice porijeklom iz tkiva jetre.
The antibody, or an antigen-binding portion thereof, for use in a method as defined in Claim 19, wherein the antibody, or antigen-binding portion thereof, is an immunoconjugate. 
Antitijelo, ili njegov antigen-vezujući dio, naznačeni time, što se upotrebljavaju u metodi definiranoj u Zahtevu 19, pri čemu je antitijelo, ili njegov antigen- vezujući dio, imunokonjugat
A compound according to claim 3 or a pharmacologically acceptable salt thereof, wherein R8a represents a C1-C4 alkyl group, and k represents 0. 
Spoj prema zahtjevu 3 ili njegova farmakološki prikladna sol, gdje a predstavlja C1-C4 alkil skupinu, i k predstavlja 0.
A compound according to claim 3 or a pharmacologically acceptable salt thereof, wherein R8a represents an ethyl group, and k represents 0. 
Spoj prema zahtjevu 3 ili njegova farmakološki prikladna sol, gdje a predstavlja etilnu skupinu, i k predstavlja 0.
A compound according to claim 7 or a pharmacologically acceptable salt thereof, wherein R3a represents a phenylmethyl group or a substituted phenylmethyl group wherein the substituent(s) represent 1 to 3 groups independently selected from substituent group a2, and substituent group a2 represents the group consisting of a methyl group, a trifluoromethyl group, and a fluoro group. 
Spoj prema zahtjevu 7 ili njegova farmakološki prikladna sol, gdje a predstavlja fenilmetil skupinu ili supstituiranu fenilmetil skupinu gdje supstituent(i) predstavlja 1 do 3 skupine nezavisno izabrane iz grupe supstituenata a2, i grupa supstituenata a2 predstavlja grupu koju čine metil skupina, trifluorometil skupina, i fluoro skupina.
A compound according to claim 10 or a pharmacologically acceptable salt thereof, wherein R8b represents a C1-C4 alkyl group. 
Spoj prema zahtjevu 10 ili njegova farmakološki prikladna sol, gdje R8b predstavlja C1-C4 alkil skupinu.
A compound according to any one of claims 1 to 12 or a pharmacologically acceptable salt thereof, wherein each of R4, R5, R6, and R7 independently represents a hydrogen atom, a C1-C2 alkyl group, a halogeno(C1-C2 alkyl) group wherein the halogeno group(s) represent 1 to 5 groups selected from the group consisting of a fluoro group and a chloro group, a fluoro group, or a chloro group. 
Spoj prema bilo kojem od zahtjeva 1 do 12 ili njegova farmakološki prikladna sol, gdje svaki od R4, R5, R6, i R7 nezavisno predstavlja atom vodika, C1-C2 alkil skupinu, halogeno(C1-C2 alkil) skupinu gdje halogenu skupinu(e) predstavlja 1 do 5 skupina izabranih iz grupe koju čine fluoro skupina i kloro skupina, fluoro skupina, ili kloro skupina.
A compound according to any one of claims 1 to 15 or a pharmacologically acceptable salt thereof, wherein B represents a naphthyl group or a substituted naphthyl group wherein the substituent(s) represent 1 to 3 groups independently selected from substituent group a3, and substituent group a3 represents the group consisting of a C1-C2 alkyl group, a halogeno(C1-C2 alkyl) group wherein the halogeno group(s) represent 1 to 5 groups selected from the group consisting of a fluoro group and a chloro group, a hydroxy group, a C1-C2 alkoxy group, a fluoro group, and a chloro group. 
Spoj prema bilo kojem od zahtjeva 1 do 15 ili njegova farmakološki prikladna sol, gdje B predstavlja naftil skupinu ili supstituiranu naftil skupinu gdje supstituent(i) predstavlja 1 do 3 skupine nezavisno izabrane iz grupe supstituenata a3, i grupa supstituenata a3 predstavlja grupu koju čine C1-C2 alkil skupina, halogeno(C1-C2 alkil) skupina gdje halogenu skupinu(e) predstavlja 1 do 5 skupina izabranih iz grupe koju čine fluoro skupina i kloro skupina, hidroksi skupina, C1-C2 alkoksi skupina, fluoro skupina, i kloro skupina.
A pharmaceutical composition according to claim 22, which is for use in the treatment or prophylaxis of hyperlipidemia, dyslipidemia, lipid metabolism abnormality, arteriosclerosis, or type II diabetes mellitus. 
Farmaceutski pripravak prema zahtjevu 22, koji je za uporabu u liječenju ili profilaksi hiperlipidemije, dislipidemije, abnormalnosti metabolizma lipida, arterioskleroze ili dijabetesa melitusa tipa II.
Use of a compound according to any one of claims 1 to 21 or a pharmacologically acceptable salt thereof in the manufacture of a medicament for use in the treatment or prophylaxis of hyperlipidemia, dyslipidemia, lipid metabolism abnormality, arteriosclerosis, or type II diabetes mellitus. 
Uporaba spoja prema bilo kojem od zahtjeva 1 do 21 ili njegove farmakološki prikladne soli u proizvodnji lijeka za uporabu u liječenju ili profilaksi hiperlipidemije, dislipidemije, abnormalnosti metabolizma lipida, arterioskleroze ili dijabetesa melitusa tipa II.
The antibody of claim 1, which is not capable of detectably binding to CLDN4 associated with the surface of a cell that expresses CLDN4 and/or is not capable of detectably binding to CLDN3 associated with the surface of a cell that expresses CLDN3, wherein binding of the antibody to CLDN4 and CLDN3 is determined by flow cytometry analysis as binding of the antibody to CLDN4 and CLDN3 expressed on the surface of intact cells. 
Antitijelo suglasno zahtjevu 1, koje je sposobno da se veže za CLDN6 asociran na membrani stanice koja eksprimira CLDN6 i koje u biti nije sposobno da se veže za CLDN9. Antitijelo suglasno zahtjevima 1 ili 2, naznačeno time da nije u biti sposobno da se veže za CLDN4, koji je asociran na membrani stanice koja eksprimira CLDN4 i/ili nije u biti sposobno da se veže za CLDN3 asociranim za membranu stanice koja eksprimira CLDN3.
A pharmaceutical composition for use in the treatment of a subject suffering from Crohn's disease comprising a pharmaceutically acceptable carrier and an amount of laquinimod or pharmaceutically acceptable salt thereof which is effective for treating a subject suffering from Crohn's disease. 
Farmaceutski sastav za primjenu u liječenju pacijenta koji pati od Crohnove bolesti, naznačen time, da sadrži farmaceutski prihvatljiv nosilac i neku količinu lakvinimoda ili njegove farmaceutski prihvatljive soli, koji je učinkovit za liječenje pacijenta koji pati od Crohnove bolesti.
The pharmaceutical composition of claim 1 or 2, wherein the amount of laquinimod is effective to reduce the Crohn's Disease Activity Index score of the subject, lower the C-Reactive Protein level of the subject, lower the fecal calprotectin level of the subject, or reduce the number of open draining fistulas in the subject. 
Farmaceutski sastav prema patentnom zahtjevu 1 ili 2, naznačen time, da količina lakvinimoda jest učinkovita da smanji vrijednost indeksa aktivnosti Crohnove bolesti kod pacijenta, da smanji razinu C-reaktivnog proteina (CRP) kod pacijenta, da smanji razinu fekalnog kalprotektina kod pacijenta ili da smanji broj vanjskih fistula kod pacijenta.
The pharmaceutical composition of any one of claims 1-5, comprising a unit dose of 0.5 mg of laquinimod or pharmaceutically acceptable salt thereof. 
Farmaceutski sastav prema bilo kojem od patentnih zahtjeva 1 - 5, naznačen time, da sadrži jediničnu dozu od 0,5 mg lakvinimoda ili njegove farmaceutski prihvatljive soli.
The pharmaceutical composition of claim 7, formulated for administration of laquinimod or pharmaceutically acceptable salt thereof at 0.5-2.0 mg/day. 
Farmaceutski sastav prema patentnom zahtjevu 7, naznačen time, da je formuliran za davanje lakvinimoda ili njegove farmaceutski prihvatljive soli uz 0,5,- 2,0 mg dnevno.
The pharmaceutical composition of any one of claims 1-12, wherein the laquinimod or pharmaceutically acceptable salt thereof is in the form of laquinimod sodium. 
Farmaceutski sastav prema bilo kojem od patentnih zahtjeva 1 - 12, naznačen time, da lakvinimod ili njegova farmaceutski prihvatljiva sol jest u obliku lakvinimod natrija.
A pharmaceutical composition consisting essentially of an amount of laquinimod or pharmaceutically acceptable salt thereof which is effective for treating a subject suffering from Crohn's disease and an amount of 5-aminosalicylic acid, antibiotics, corticosteroids, immunosuppressors, TNFa agents, or anti-integrins. 
Farmaceutski sastav, naznačen time, da u biti sadrži neku količinu lakvinimoda ili njegove farmaceutski prihvatljive soli, koja je učinkovita za liječenje pacijenta koji pati od Crohnove bolesti, te neku količinu 5-aminosalicilne kiseline, antibiotika, kortikosteroida, imunosupresivnih lijekova, TNFa agensa ili anti-integrina.
A single-stranded antisense oligomer of 10 to 50 nucleotides in length having a contiguous nucleobase sequence with at least 80% sequence identity to a complementary region of a nucleic acid which encodes the COMPLEMENT COMPONENT 6 (C6) sequence represented by SEQ ID NO: 1; the oligomer comprising at least one nucleotide analogue and being capable of reducing the level of C6 mRNA expression in a mammal by at least 20% as determined by a qPCR assay, wherein the oligomer is targeted to nucleotides 112-152, 433-473, 546-586, 706-746, or 1015-1055 from the ATG start site of SEQ ID NO: 1. 
Jednolančani antisense oligomer duljine od 10 do 50 nukleotida koji ima graničnu nukleobaznu sekvenciju s bar 80% sekvencijske identičnosti s komplementarnom regijom nukleinske kiseline koja kodira KOMPLEMENTARNU KOMPONENTU 6 (C6) sekvence predstavljene SEQ ID NO: 1; oligomer sadrži najmanje jedan analog nukleotida a koji ima sposobnost reduciranja razine C6 mRNA ekspresije u sisavaca za najmanje 20% kako je određeno pomoću qPCR testa, naznačen time da je oligomer targetiran na nukleotide 112-152, 433-473, 546 -586, 706-746 ili 1015-1055 iz ATG start mjesta SEQ ID NO: 1.
The oligomer of claim 1, wherein the nucleotide analogue is a modified sugar moiety selected from the group consisting of: 2'-O-methoxyethyl modified sugar moiety, a 2'-methoxy modified sugar moiety, a 2'-O-alkyl modified sugar moiety, and a bicyclic sugar moiety. 
Oligomer prema zahtjevu 1, naznačen time da je analog nukleotida modificirani šećerni dio odabran iz skupine koja se sastoji od: 2'-O-metoksietil modificirani šećerni dio, 2'-metoksi modificirani šećerni dio, 2'-O-alkil modificirani šećera dio i biciklički šećerni dio.
The oligomer of claim 3, wherein the bicyclic sugar moiety is a locked nucleic acid (LNA) monomer. 
Oligomer prema zahtjevu 3, naznačen time da je biciklički šećerni dio monomer zaključane nukleinske kiseline (LNA).
The oligomer of claim 2, wherein the modified internucleoside linkage is a phosphorothioate internucleoside linkage. 
Oligomer prema zahtjevu 2, naznačen time da je modificirana internukleotidna spojnica fosforotioatna internukleotidna spojnica.
The oligomer of claim 2, wherein the modified nucleobase is 5-methylcytosine. 
Oligomer prema zahtjevu 2, naznačen time da je modificirana nukleobaza 5-metilcitozin.
The oligomer of claim 1 or 9, wherein the oligomer has at least 90%, 96%, 97%, 98% or 99% sequence identity to Complement Component C6 sequence represented by SEQ ID NO:1. 
Oligomer prema zahtjevu 1 ili 9, naznačen time da oligomer ima najmanje 90%, 96%, 97%, 98% ili 99% sekvencijske identičnosti s KOMPLEMENTARNOM KOMPONENTOM C6 sekvence predstavljene SEQ ID NO: 1.
The use of claim 13, wherein the chronic demyelinating condition is multiple sclerosis, a chronic demyelinating neuropathy, HMSN (CMT) disease type IA and IB, Alzheimer's disease, Huntington's disease, Charcot-Marie-Tooth disease, amyotrophic lateral sclerosis (ALS), Guillain-Barre syndrome (GBS, also known as acute inflammatory demyelinating polyneuropathy or AIDP), leukodystrophy, or Parkinson's disease. 
Uporaba prema zahtjevu 13, naznačena time da je kronično demijelinizirajuće stanje multipla skleroza, kronična demijelinacijska neuropatija, HMSN (CMT) tipa bolesti IA i IB, Alzheimerova bolest, Huntingtonova bolest, Charcot-Marie-Tooth bolest, amiotrofna lateralna skleroza (ALS), Guillain-Barre sindrom (GBS, također poznat kao akutna upalna demijelinacijska polineuropatija ili AIDP), leukodistrofija, ili Parkinsonova bolest.
The use according to claim 1, for the prevention and/or treatment of polycystic ovary syndrome. 
Uporaba prema zahtjevu 1, za prevenciju i/ili liječenje sindroma policističnih jajnika.
A method for the treatment and/or prevention of hyperandrogenism and/or polycystic ovary syndrome and/or related disorders comprising the vaginal administration of at least one insulin-sensitising agent. A pharmaceutical formulation for vaginal administration comprising at least one insulin-sensitising agent for use in the prevention and/or treatment of hyperandrogenism and/or polycystic ovary syndrome and/or related disorders. 
Farmaceutski pripravak koji sadrži barem jedno sredstvo koje povećava osjetljivost na inzulin za uporabu u prevenciji i/ili liječenju hiperandrogenizma i/ili sindroma policističnih jajnika i/ili barem jednog povezanog poremećaja iz skupine koju čine: hirzutizam, akne, gubitak kose, prekomjerna težina, pretilost, nepravilni, sporadični ili izostali menstrualni ciklusi, povećani i/ili policistični jajnici i neplodnost; pri čemu se taj farmaceutski pripravak primjenjuje vaginalno.
is selected from the group consisting of H, straight or branched (C1-C6) alkyl, and (C1-C6)alkyl-C(O)-; 
je odabran iz skupine koju čine H, ravnolančani ili razgranati (C1-C6)alkil, i (C1-C6)alkil-C(O)-;
with the proviso that the compound according to Formula I is not 1-amine-2-(3-boronopropyl)cyclohexane carboxylic acid. 
uz uvjet da spoj prema Formuli I nije 1-amino-2-(3-borpropil)cikloheksan karboksilna kiselina.
The compound according to claim 1, wherein D is straight or branched (C3-C5)alkylene. 
Spoj prema zahtjevu 1, naznačen time da D je ravnolančani ili razgranati (C3-C5)alkilen.
The compound according to claim 1 that is selected from the following table: 
Spoj prema zahtjevu 1, naznačen time da je izabran iz slijedeće tablice:
A compound according to claim 1 that is selected from the following table: 
Spoj prema zahtjevu 1, naznačen time da je izabran iz sljedeće tablice:
A compound for use according to claim 14, wherein the disease or condition is selected from pulmonary hypertension, erectile dysfunction, hypertension, atherosclerosis, renal disease, asthma, T-cell dysfunction, ischemia reperfusion injury, neurodegenerative diseases, wound healing, and fibrotic diseases. 
Spoj za uporabu prema zahtjevu 14, naznačen time da je bolest ili stanje izabrano iz plućne hipertenzije, erektilne disfunkcije, hipertenzije, ateroskleroze, bubrežnih bolesti, astma, disfunkcije T-stanica, ishemično-reperfuzijskih ozljeda, neuro-degenerativnih bolesti, zacjeljivanja rana i fibroznih oboljenja.
contacting an acid solvate of a compound of formula II: with an amide under conditions suitable for forming an amide solvate of the compound of formula II; and 
kontaktiranje kiselog solvata spoja s formulom II: [image] s amidom pod uvjetima pogodnim za nastajanje amidnog solvata spoja s formulom II; te
contacting the amide solvate with an aqueous base comprising sodium ions under conditions suitable for forming the compound of formula I. 
kontaktiranje amidnog solvata s vodenom bazom koja sadrži natrijeve ione pod uvjetima pogodnim za nastajanje spoja s formulom I.
The process of Claim 1, wherein the acid component of the acid solvate of the compound of formula II is a carboxylic acid, preferably wherein the carboxylic acid is R1COOH wherein R1 is -H or a C1-C4 alkyl optionally substituted with up to three halo. 
Postupak prema zahtjevu 1, naznačen time da kisela komponenta kiselog solvata spoja s formulom II je karboksilna kiselina, poželjno pri čemu karboksilna kiselina je R1COOH pri čemu R1 je -H ili C1-C4 alkil proizvoljno supstituiran s do tri halo atoma.
The process of Claim 5, wherein the amide is the N,N-dialkylformamide; and the conditions suitable for forming the amide solvate of the compound of formula II comprise a temperature of between about 20 °C and about 70 °C; preferably wherein: the amide is N,N-dimethylformamide (DMF); and the conditions suitable for forming the amide solvate comprise re-slurrying of the acid solvate in the DMF at a temperature of about 50 °C. 
Postupak prema zahtjevu 5, naznačen time da amid je N,N-dialkilformamid; te pogodni uvjeti za nastanak amidnog solvata spoja s formulom II obuhvaćaju temperaturu od između oko 20 °C i oko 70 °C; poželjno pri čemu: amid je N,N-dimetilformamid (DMF); i t pogodni uvjeti za nastanak amidnog solvata obuhvaćaju ponovno suspendiranje kiselog solvata u DMF kod temperature od oko 50 °C.
the aqueous base in step b) comprises sodium hydroxide (NaOH) and isopropyl alcohol (IPA), and the conditions suitable for forming the compound of formula I comprise a temperature of about 80 °C and a pH of about 9. 
vodena baza u koraku b) sadrži natrijev hidroksid (NaOH) i izopropil alkohol (IPA), te pogodni uvjeti za nastanak spoja s formulom I obuhvaćaju temperaturu od oko 80 °C i pH od oko 9.
A compound of formula III: 
Spoj s formulom III: [image]
A process for preparing a compound of formula VI: comprising providing a combination of a compound of formula V: stabilised with an amide; and then contacting a compound of formula IV: with the combination of the compound of formula V in the presence of the amide, wherein: 
Postupak za pripremanje spoja s formulom VI: [image] naznačen time da sadrži osiguravanje kombinacije spoja s formulom V: [image] stabiliziranje s amidom; i zatim kontaktiranje spoja s formulom IV: [image] s kombinacijom spoja s formulom V u prisutnosti amida, pri čemu:
under conditions suitable for forming a compound of formula VI. 
pod uvjetima pogodnim za tvorbu spoja s formulom VI.
the conditions sufficient to produce the compound of formula VI comprise: 
dovoljni uvjeti za nastajanje spoja s formulom VI obuhvaćaju:
the compound of formula VI is not isolated; or 
spoj s formulom VI nije izoliran; ili
The process according to claim 1 or 10 wherein the compound of formula I is in the form of a hydrate, preferably a hexahydrate. 
Postupak prema zahtjevu 1 ili 10 naznačen time da je spoj s formulom I u obliku hidrata, poželjno u obliku heksahidrata.
Use of an amide to stabilize a compound of formula V as defined in claim 9. 
Uporaba amida naznačena time da se koristi za stabiliziranje spoja s formulom V kako je definirano u zahtjevu 9.
A disposable absorbent article as described in claim 1, characterised in that the permeable top sheet is a nonwoven with a weight between 10 and 15 g/m2, formed from bicomponent fibres of the core and sheath type, with the core containing 80 to 100% of polylactic acid and the sheath containing 80 to 100% of polypropylene. A disposable absorbent article as described in claim 1, characterised in that the permeable top sheet is a nonwoven with a weight between 10 and 15 g/m2, formed from bicomponent fibres of the core and sheath type, with the core containing 80 to 100% of poly- hydroxy-alcanoate lactic acid and sheath containing 80 to 100% of polypropylene. 
kao elastična sredstava: lateks, prirodnu gumu ili elastični materijale koji sadržavaju poliolefin i sredstvo za poboljšanje razgradnje; kao sustav pričvršćivanja: par traka i prednju traku izrađenu od PHA ili PLA ili polietilena ili polipropilena koji sadržava sredstvo za poboljšanje razgradnje; kao sredstvo za spajanje: ljepilo koje sadržava PHA ili PLA i pri čemu je gornji sloj proizvoda netkani materijal s težinom između 10 i 15 g/m2, formiran iz dvokomponentnih vlakana s jezgrom i omotačem, s jezgrom koja sadržava 80 do 100 % polimliječne kiseline i omotača koji sadržava 80 do 100 % polipropilena.
A disposable absorbent article as described in any of the preceding claims, characterised in that the impermeable back sheet is a film of low density polyethylene with a weight of about 10-25 g/m2, containing a pro-degrading agent which contains saponified fatty acids and calcium. 
Upijajući proizvod za jednokratnu upotrebu u skladu s prethodnim patentnim zahtjevom, naznačen time, da je nepropusni donji sloj film od polietilena niske gustoće, težine od oko 10 do 25 g/m2, koji sadržava sredstvo za poboljšanje razgradnje koje sadržava saponificirane masne kiseline i kalcij.
A disposable absorbent article as described in claims 5, 6 and 7, characterised in that the impermeable back sheet is laminated with a nonwoven fabric of about 10 and 15 g/m2 and containing bicomponent core and sheath fibres, with the core containing about 80 to about 100% polylactic acid and the sheath containing about 80 to 100% polypropylene. 
Upijajući proizvod za jednokratnu upotrebu u skladu s patentnim zahtjevima 1 do 2, naznačen time, da je nepropusni donji sloj laminiran s netkanim materijalom oko 10 i 15 g/m2 i sadržava dvokomponentna vlakna s jezgrom i omotačem, pri čemu jezgra sadržava oko 80 do približno 100 % polimliječne kiseline i omotač sadržava približno 80 do 100 % polipropilena.
A disposable absorbent article as described in any of the preceding claims, characterised in that the absorbent core is formed of cellulose fibres and two kinds of particles, homogeneously mixed: 
Upijajući proizvod za jednokratnu upotrebu u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time, da je superapsorbirajuća jezgra načinjena od celuloznih vlakana i dvije vrste homogeno pomiješanih čestica:
A disposable absorbent article as described in any of claims 1 to 13, characterised in that the external barriers cuffs are formed from a nonwoven fabric with a weight of about 10 to about 15 gr / m2, formed of bicomponent core and sheath fibres, with the core containing about 80 to about 100% poly-hydroxy-alcanoates and the sheath containing about 80 to about 100% polypropylene. 
Upijajući proizvod za jednokratnu upotrebu u skladu s bilo kojim patentnim zahtjevom 1 do 10, naznačen time, da su nabrane vanjske stijenke oblikovane od netkanog materijala težine od oko 10 do oko 15 g/m2, načinjene od dvokomponentnih vlakana s jezgrom i omotačem, s jezgrom koja sadržava oko 80 do približno 100 % polihidroksialkanoata i omotač sadržava oko 80 do približno 100 % polipropilena.
A disposable absorbent article as described in any of claims 1 to 13, characterised in that the external barriers cuffs are formed from a nonwoven film with a weight of about 10 to about 15 gr / m2 containing at least 15% of cotton fibres. 
Upijajući proizvod za jednokratnu upotrebu u skladu s bilo kojim patentnim zahtjevom 1 do 10, naznačen time, da su nabrane vanjske stijenke oblikovane od netkanog filma mase od oko 10 do oko 15 g/m2, koji sadržava najmanje 15 % pamučnih vlakana.
A disposable absorbent article as described in any of claims 1 to 20, characterised in that it contains stretch zones which consist of an elastomeric material placed between two films; the elastomeric material is a polyolefin plus a pro-degrading agent containing saponified fatty acids and calcium and the films are nonwoven fabrics of about 10-15 gr/m2, which are formed by bicomponent core and sheath fibres, with the core containing about 80 to about 100% of polylactic acid and the sheath containing of about 80 to 100% of polypropylene. 
Upijajući proizvod za jednokratnu upotrebu u skladu s bilo kojim od patentnih zahtjeva 1 do 16, naznačen time, da sadržava područja rastezanja koja se sastoje od elastomernog materijala postavljenog između dva filma; elastomerni materijal je poliolefin i sredstvo za poboljšanje razgradnje koje sadržava saponificirane masne kiseline i kalcij i filmovi su netkani materijali od oko 10 do 15 g/m2, koji su formirani od dvokomponentnih vlakana s jezgrom i omotačem, pri čemu jezgra sadržava oko 80 do oko 100 % polimliječne kiseline i omotač sadržava od oko 80 do 100 % polipropilena.